Diabetes Plus China Equals Lilly’s Emerging Markets Strategy
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly Emerging Markets President Jacques Tapiero told the Morgan Stanley Healthcare Conference that China is a “must win”, backed by diabetes brands and a near-term pipeline.
You may also be interested in...
A Silver Lining In Lilly’s Solanezumab Alzheimer’s Failure?
Drug fails all primary endpoints in two Phase III studies, following in the footsteps of Pfizer/Janssen’s bapineuzumab. But Lilly points to a secondary signal in pooled data as a sign of some effect on cognitive decline.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.